Back to today’s briefing

Story perspectives

OFA Sues FDA Over Semaglutide Shortage Decision

2/26/2025

40 6

Summary

Story summary

The Outsourcing Facilities Association (OFA) is taking a stand against the FDA, suing over the removal of semaglutide from the drug shortage list. They argue that this decision overlooks persistent shortages. Meanwhile, compounding pharmacies can produce semaglutide until 2025, as Novo Nordisk commits a staggering $6.5 billion to ramp up production.

1 of 1

Story summary

The Outsourcing Facilities Association (OFA) is taking a stand against the FDA, suing over the removal of semaglutide from the drug shortage list. They argue that this decision overlooks persistent shortages. Meanwhile, compounding pharmacies can produce semaglutide until 2025, as Novo Nordisk commits a staggering $6.5 billion to ramp up production.